Aminopyridinecarboxamide-based inhibitors: Structure–activity relationship

D. Bonafoux(Pfizer (United States)), Jeanette L. Glaenzer(Pfizer (United States)), Sumathy Mathialagan(Pfizer (United States)), Francis J. Koszyk(Pfizer (United States)), Sheri L. Bonar(Washington University in St. Louis), Julia A. Guzova(Pfizer (United States)), Sharon Rouw(Pfizer (United States)), Cynthia D. Sommers(Pfizer (United States)), Nandidni N. Kishore(Pfizer (United States)), Adam H. Libby(Pfizer (United States)), Richard M. Weier(Pfizer (United States)), David S. Oburn(Pfizer (United States)), Michael Clare(National Oceanography Centre), Catherine S. Tripp(Pfizer (United States)), Patrick J. Lennon(Pfizer (United States)), He Huang(Renmin University of China), Lori J. Vanella(Pfizer (United States)), H. T. Huang, Serge G. Wolfson(Pfizer (United States)), Ann M. Donnelly(Pfizer (United States))
Bioorganic & Medicinal Chemistry
October 28, 2009
Cited by 7


Related Papers